# The LANCET Trial: A Trial of Long-acting Insulin Injection to Reduce C-reactive Protein in Patients With Type 2 Diabetes

> **NCT00366301** · PHASE4 · TERMINATED · sponsor: **Brigham and Women's Hospital** · enrollment: 500 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Insulin glargine injection
- **DRUG:** metformin
- **DRUG:** Placebo pill

## Key facts

- **NCT ID:** NCT00366301
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-08
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 500 (ACTUAL)
- **Why stopped:** Interim analyses demonstrated futility. Thus, recruitment curtailed 10/08.
- **Last updated:** 2010-11-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00366301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00366301, "The LANCET Trial: A Trial of Long-acting Insulin Injection to Reduce C-reactive Protein in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00366301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*